ES2202368T3 - Hibridos vectoriales retrovirales y su uso para la transferencia genica. - Google Patents

Hibridos vectoriales retrovirales y su uso para la transferencia genica.

Info

Publication number: ES2202368T3
Authority: ES; Spain
Prior art keywords: region; virus; gene; ltr; vector
Prior art date: 1994-09-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES95929100T

Other languages

English (en)

Spanish (es)

Inventor

Christopher Baum

Carol Stocking-Harbers

Wolfram Ostertag

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Vision 7 GmbH

Original Assignee

Vision 7 GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-09-08

Filing date

1995-08-10

Publication date

2004-04-01

1995-02-07 Priority claimed from DE19503952A external-priority patent/DE19503952A1/de

1995-08-10 Application filed by Vision 7 GmbH filed Critical Vision 7 GmbH

2004-04-01 Application granted granted Critical

2004-04-01 Publication of ES2202368T3 publication Critical patent/ES2202368T3/es

2015-08-10 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 113
239000013598 vector Substances 0.000 title claims abstract description 105
230000001177 retroviral effect Effects 0.000 title claims abstract description 57
238000012546 transfer Methods 0.000 title abstract description 32
241000700605 Viruses Species 0.000 claims abstract description 52
210000004027 cell Anatomy 0.000 claims description 59
230000010076 replication Effects 0.000 claims description 32
208000015181 infectious disease Diseases 0.000 claims description 20
230000002950 deficient Effects 0.000 claims description 15
238000004806 packaging method and process Methods 0.000 claims description 15
241000714188 Friend murine leukemia virus Species 0.000 claims description 12
239000002245 particle Substances 0.000 claims description 12
230000006870 function Effects 0.000 claims description 11
101150046368 PSF1 gene Proteins 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 10
241000713883 Myeloproliferative sarcoma virus Species 0.000 claims description 9
238000000034 method Methods 0.000 claims description 9
210000001671 embryonic stem cell Anatomy 0.000 claims description 8
210000003527 eukaryotic cell Anatomy 0.000 claims description 8
101100465853 Caenorhabditis elegans psf-2 gene Proteins 0.000 claims description 7
238000001727 in vivo Methods 0.000 claims description 7
230000002458 infectious effect Effects 0.000 claims description 7
230000007717 exclusion Effects 0.000 claims description 5
238000001415 gene therapy Methods 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
238000010361 transduction Methods 0.000 claims description 5
230000026683 transduction Effects 0.000 claims description 5
238000001890 transfection Methods 0.000 claims description 4
230000003612 virological effect Effects 0.000 claims description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
210000002443 helper t lymphocyte Anatomy 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 2
238000002955 isolation Methods 0.000 claims description 2
210000000130 stem cell Anatomy 0.000 abstract description 15
241001529936 Murinae Species 0.000 abstract description 8
230000003394 haemopoietic effect Effects 0.000 abstract description 5
208000032839 leukemia Diseases 0.000 abstract description 2
230000014509 gene expression Effects 0.000 description 33
230000035772 mutation Effects 0.000 description 28
241001430294 unidentified retrovirus Species 0.000 description 25
238000003780 insertion Methods 0.000 description 15
230000037431 insertion Effects 0.000 description 15
230000010354 integration Effects 0.000 description 15
239000012634 fragment Substances 0.000 description 13
238000010367 cloning Methods 0.000 description 12
239000002243 precursor Substances 0.000 description 12
210000003958 hematopoietic stem cell Anatomy 0.000 description 11
230000030279 gene silencing Effects 0.000 description 10
210000000066 myeloid cell Anatomy 0.000 description 10
108020004414 DNA Proteins 0.000 description 9
230000000694 effects Effects 0.000 description 9
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 8
102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 8
108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 8
206010028980 Neoplasm Diseases 0.000 description 8
238000002703 mutagenesis Methods 0.000 description 8
231100000350 mutagenesis Toxicity 0.000 description 8
239000002773 nucleotide Substances 0.000 description 8
125000003729 nucleotide group Chemical group 0.000 description 8
239000013612 plasmid Substances 0.000 description 8
230000008901 benefit Effects 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
230000003584 silencer Effects 0.000 description 7
108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
206010048723 Multiple-drug resistance Diseases 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
241000237955 Nassarius Species 0.000 description 6
230000004913 activation Effects 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
241000713880 Spleen focus-forming virus Species 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
238000002512 chemotherapy Methods 0.000 description 5
210000002950 fibroblast Anatomy 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 4
101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
241001483952 Peach chlorotic mottle virus Species 0.000 description 4
102100037204 Sal-like protein 1 Human genes 0.000 description 4
108091023040 Transcription factor Proteins 0.000 description 4
102000040945 Transcription factor Human genes 0.000 description 4
229960001338 colchicine Drugs 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
239000000824 cytostatic agent Substances 0.000 description 4
230000001085 cytostatic effect Effects 0.000 description 4
230000009849 deactivation Effects 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
230000001413 cellular effect Effects 0.000 description 3
238000010276 construction Methods 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
210000003643 myeloid progenitor cell Anatomy 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
238000003146 transient transfection Methods 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
229920001817 Agar Polymers 0.000 description 2
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
208000036566 Erythroleukaemia Diseases 0.000 description 2
208000024556 Mendelian disease Diseases 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
108010067390 Viral Proteins Proteins 0.000 description 2
208000021841 acute erythroid leukemia Diseases 0.000 description 2
239000008272 agar Substances 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000012937 correction Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000002372 labelling Methods 0.000 description 2
230000001926 lymphatic effect Effects 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000005457 optimization Methods 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
230000000392 somatic effect Effects 0.000 description 2
JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
102000002226 Alkyl and Aryl Transferases Human genes 0.000 description 1
108010014722 Alkyl and Aryl Transferases Proteins 0.000 description 1
101100227322 Caenorhabditis elegans fli-1 gene Proteins 0.000 description 1
101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000714181 Friend mink cell focus-forming virus Species 0.000 description 1
101710177291 Gag polyprotein Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
241000713858 Harvey murine sarcoma virus Species 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
108700041567 MDR Genes Proteins 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
241000714178 Mink cell focus-forming virus Species 0.000 description 1
241000713862 Moloney murine sarcoma virus Species 0.000 description 1
206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101100281205 Mus musculus Fli1 gene Proteins 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
101100257820 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ssp-1 gene Proteins 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
102000007999 Nuclear Proteins Human genes 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
208000008601 Polycythemia Diseases 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
108700005075 Regulator Genes Proteins 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
101150052859 Slc9a1 gene Proteins 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
102100030246 Transcription factor Sp1 Human genes 0.000 description 1
101710085924 Transcription factor Sp1 Proteins 0.000 description 1
101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
XDFCIPNJCBUZJN-UHFFFAOYSA-N barium(2+) Chemical compound [Ba+2] XDFCIPNJCBUZJN-UHFFFAOYSA-N 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
244000309466 calf Species 0.000 description 1
101150055766 cat gene Proteins 0.000 description 1
230000009134 cell regulation Effects 0.000 description 1
229930183167 cerebroside Natural products 0.000 description 1
RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
230000008859 change Effects 0.000 description 1
238000003501 co-culture Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000003328 fibroblastic effect Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
231100000707 mutagenic chemical Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
230000003039 myelosuppressive effect Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
230000001566 pro-viral effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Toxicology (AREA)
Plant Pathology (AREA)
Immunology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

ES95929100T 1994-09-08 1995-08-10 Hibridos vectoriales retrovirales y su uso para la transferencia genica. Expired - Lifetime ES2202368T3 (es)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DE4431973		1994-09-08
DE4431973		1994-09-08
DE19503952		1995-02-07
DE19503952A DE19503952A1 (de)	1994-09-08	1995-02-07	Retrovirale Vektorhybride und deren Verwendung zum Gentransfer

Publications (1)

Publication Number	Publication Date
ES2202368T3 true ES2202368T3 (es)	2004-04-01

Family

ID=25939938

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES95929100T Expired - Lifetime ES2202368T3 (es)	1994-09-08	1995-08-10	Hibridos vectoriales retrovirales y su uso para la transferencia genica.

Country Status (9)

Country	Link
US (1)	US5858744A (de)
EP (1)	EP0781343B1 (de)
JP (1)	JPH09511405A (de)
AT (1)	ATE244310T1 (de)
AU (1)	AU3258295A (de)
DK (1)	DK0781343T3 (de)
ES (1)	ES2202368T3 (de)
PT (1)	PT781343E (de)
WO (1)	WO1996007747A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19704979A1 (de) *	1996-02-07	1997-08-14	Max Delbrueck Centrum	Retroviraler Vektor für den Gentransfer eines IL6-Antagonisten in humane hämatopoetische Stammzellen
DE19822115B4 (de) *	1998-05-08	2004-04-08	Heinrich-Pette-Institut	Retrovirale Gentransfervektoren
KR20000006334A (ko) *	1998-06-26	2000-01-25	이선경	바이러스코딩염기서열이전혀없는고효율레트로바이러스벡터
WO2000023606A1 (en)	1998-10-22	2000-04-27	Medical College Of Georgia Institute, Inc.	Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors
US6534300B1 (en)	1999-09-14	2003-03-18	Genzyme Glycobiology Research Institute, Inc.	Methods for producing highly phosphorylated lysosomal hydrolases
US6770468B1 (en)	1999-09-14	2004-08-03	Genzyme Glycobiology Research Institute, Inc.	Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
DE19957838C2 (de)	1999-11-25	2002-11-21	Pette Heinrich Inst	Gentherapie von HIV-Infizierten durch Expression von Membran-verankerten gp41-Peptiden
WO2001090391A2 (en) *	2000-05-19	2001-11-29	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Utilization of non-viral sequences for minus-strand dna transfer and gene reconstitution
US20030124652A1 (en) *	2001-12-21	2003-07-03	Novazyme Pharmaceuticals, Inc.	Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
US6905856B2 (en) *	2001-12-21	2005-06-14	Genzyme Glycobiology Research Institute, Inc.	Soluble GlcNAc phosphotransferase
US6800472B2 (en) *	2001-12-21	2004-10-05	Genzyme Glycobiology Research Institute, Inc.	Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
WO2013026015A1 (en)	2011-08-18	2013-02-21	Dana-Farber Cancer Institute, Inc.	Muc1 ligand traps for use in treating cancers
CN103842501B (zh) *	2011-10-05	2017-12-08	莫尔梅德股份有限公司	病毒载体纯化系统
US20170002064A1 (en)	2013-11-08	2017-01-05	The Board Of Regents Of The University Of Texas System	Vh4 antibodies against gray matter neuron and astrocyte
WO2015116753A1 (en)	2014-01-29	2015-08-06	Dana-Farber Cancer Institute, Inc.	Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
RS65666B1 (sr)	2015-11-09	2024-07-31	Childrens Hospital Philadelphia	Glipikan 2 kao tumor marker i terapijski cilj
CN120484131A (zh)	2019-07-19	2025-08-15	费城儿童医院	包含磷脂酰肌醇蛋白聚糖2结合结构域的嵌合抗原受体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0672119A4 (de) *	1992-10-16	1997-06-04	Univ Columbia	Retroviral vermittelter transfer des menschlichen gens für die resistenz gegen vielfachdrogen.
FR2699191B1 (fr) *	1992-12-16	1995-02-10	Univ Paris Curie	Nouveaux vecteurs rétroviraux, lignées cellulaires les contenant, et leur utilisation dans le traitement des tumeurs.

1995
- 1995-08-10 JP JP8509149A patent/JPH09511405A/ja active Pending
- 1995-08-10 AT AT95929100T patent/ATE244310T1/de not_active IP Right Cessation
- 1995-08-10 PT PT95929100T patent/PT781343E/pt unknown
- 1995-08-10 EP EP95929100A patent/EP0781343B1/de not_active Expired - Lifetime
- 1995-08-10 ES ES95929100T patent/ES2202368T3/es not_active Expired - Lifetime
- 1995-08-10 WO PCT/EP1995/003175 patent/WO1996007747A1/de not_active Ceased
- 1995-08-10 AU AU32582/95A patent/AU3258295A/en not_active Abandoned
- 1995-08-10 DK DK95929100T patent/DK0781343T3/da active
- 1995-08-10 US US08/793,610 patent/US5858744A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP0781343B1 (de)	2003-07-02
DK0781343T3 (da)	2003-10-27
WO1996007747A1 (de)	1996-03-14
JPH09511405A (ja)	1997-11-18
US5858744A (en)	1999-01-12
AU3258295A (en)	1996-03-27
PT781343E (pt)	2003-11-28
EP0781343A1 (de)	1997-07-02
ATE244310T1 (de)	2003-07-15

Publication	Publication Date	Title
ES2202368T3 (es)	2004-04-01	Hibridos vectoriales retrovirales y su uso para la transferencia genica.
ES2297831T3 (es)	2008-05-01	Vectores retroviricos que presentan una tasa de recombinacion reducida.
Vile et al.	1995	Retroviruses as vectors
JP4418536B2 (ja)	2010-02-17	レトロウイルスベクター
ES2618508T3 (es)	2017-06-21	Células que comprenden partículas lentivíricas con codones optimizados
US6949242B2 (en)	2005-09-27	Retroviral vector for the transfer and expression of genes for therapeutic purposes in eukaryotic cells
ES2384553T3 (es)	2012-07-06	Utilización de secuencias de adn de estructura triple para la transferencia de secuencias nucleotídicas
ES2323744T3 (es)	2009-07-23	Sistema retroviral de suministro de genes y metodos de uso.
US5714353A (en)	1998-02-03	Safe vectors for gene therapy
ES2298745T3 (es)	2008-05-16	Promotores bidireccionales de sintesis y utilizacion de los mismos.
US6899871B2 (en)	2005-05-31	Gene delivery system and methods of use
US8673612B2 (en)	2014-03-18	Synthetic viruses and uses thereof
JP4482578B2 (ja)	2010-06-16	真核細胞にヌクレオチド配列を挿入し得る天然または合成のレトロエレメント配列
JP2018526007A (ja)	2018-09-13	２ａペプチドを含む組換えベクター
JPH08507687A (ja)	1996-08-20	遺伝子治療用の改良されたベクター
Heaney et al.	1986	Site-directed mutagenesis of the gag-myc gene of avian myelocytomatosis virus 29: biological activity and intracellular localization of structurally altered proteins
Schmidt et al.	1997	Long terminal repeat U3 length polymorphism of human foamy virus
EP0835320A1 (de)	1998-04-15	Verbesserte retroviralen vektoren, besonders angepasst zur gen-therapie
JPH11507244A (ja)	1999-06-29	Ｓｒｖ−３エンベロープ糖タンパク質配列で偽型化したレトロウイルスベクター
US20050112098A1 (en)	2005-05-26	Pseudotyped viruses and methods for their use
CA2199131C (en)	2007-04-10	Retroviral vector hybrids and the use thereof for gene transfer
ES2236888T3 (es)	2005-07-16	Expresion de una proteina modificada de la envoltura del virus espumoso.
Robbins	1999	Retroviral vectors
ES2235638B1 (es)	2006-10-16	Nuevo vector retroviral de alto titulo y metodos de transduccion.
Lang et al.	1994	Development of transforming function during transduction of proto-ras into Harvey sarcoma virus.